Equillium Inc

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.

Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial  reduction in baseline corticosteroid use

Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at Decheng Capital, has been appointed to Equillium's board of directors, effective Thursday, February 4, 2021.

Equillium Announces the Appointment of Katherine Xu to the Board of Directors

LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced registered direct offering with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit was $7.00, priced above the market under Nasdaq rules. The warrants have an exercise price of $14.00 per share, are immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00.

Equillium Announces Closing of $30 Million Registered Direct Offering

Equillium Inc (NASDAQ: EQ) has entered into a securities purchase agreement with Decheng Capital to purchase around 4.3 million units from Equillium at $7 per unit, equivalent to gross proceeds of $30 million. EQ's closing price as of Wednesday was $6.62 per share.

Equillium Raises $30M Via Equity, Shares Rally

LA JOLLA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a securities purchase agreement with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit is $7.00, priced above the market under Nasdaq rules. The warrants will have an exercise price of $14.00 per share, will be immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00.

Equillium Announces Pricing of $30 Million Registered Direct Offering

LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) has been accepted as a late-breaking oral presentation at the 2021 TCT Meetings Digital Experience, being held February 8-12, 2021.

Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience

Studies further support itolizumab's potential as treatment for aGVHD patients Studies further support itolizumab's potential as treatment for aGVHD patients

Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society of Hematology Annual Meeting and Exposition

Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.

Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19

Shares of Equillium Inc. tumbled 12.6% in premarket trading Wednesday, after the biotechnology company said it decided not to initiate a Phase 3 trial its itolizumab for the treatment of hospitalized COVID-19 patients "at this time." The company said its decision was based on a review of recent updates regarding the efficacy of COVID-19 vaccine candidates and other treatment options.

Equillium's stock tumbles after decision to not initiate late-stage trial of COVID-19 treatment

Analyst Day scheduled for December 4, 2020 Analyst Day scheduled for December 4, 2020

Equillium Provides Itolizumab COVID-19 Program Update

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2020.  

Equillium Reports Third Quarter 2020 Financial Results and Business Highlights

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium's chief executive officer and Krishna Polu, M.D., Equillium's chief medical officer, will present at two upcoming investor conferences in November 2020.

Equillium to Present at Investor Conferences in November 2020

100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date

Equillium Announces Positive Interim Data of Itolizumab in the First-line Treatment of Acute Graft-Versus-Host Disease

Studies  further validate  ongoing clinical  development of itolizumab for the treatment  of  systemic  lupus   erythematosus and lupus  nephritis

Equillium to Present Data at the 2020 American College of Rheumatology Meeting Demonstrating CD6 Modulation Improves Kidney and Skin Pathology in Preclinical Models of Systemic Lupus Erythematosus

Equillium (EQ) stock is seeing gains on Friday after getting the go-ahead from the FDA for a drug trial treating the coronavirus. The post EQ Stock: 6 Things to Know about Biotech Company Equillium appeared first on InvestorPlace.

EQ Stock: 6 Things to Know about Biotech Company Equillium

Equillium Inc. (NASDAQ: EQ) shares jumped on Friday after the company announced a key update from the U.S.

What This FDA Update Means for Equillium's COVID-19 Study

Equillium p lans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4  2020

Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial

Is (EQ) Outperforming Other Medical Stocks This Year?

Is Equillium (EQ) Stock Outpacing Its Medical Peers This Year?

LA JOLLA, Calif., Sept.  17, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that data supporting the CD6-ALCAM pathway as a relevant target for therapeutic intervention in patients with uncontrolled asthma was presented in an oral presentation and two posters at the virtual European Respiratory Society (ERS) International Congress 2020 held September 7-9, 2020.

Equillium Presented New Data and Insights on the CD6-ALCAM Pathway in Uncontrolled Asthma at the European Respiratory Society International Congress 2020

Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020

Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients

LA JOLLA, Calif., Sept.  03, 2020  (GLOBE NEWSWIRE) --  Equillium, Inc.  (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., Equillium’s chief medical officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020.

Equillium to Present at H.C. Wainwright 22nd Annual Global Investment Conference

LA JOLLA, Calif., Aug.  18, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of common stock at a public offering price of $7.00 per share. The aggregate gross proceeds to Equillium from this offering, before deducting underwriting discounts and commissions and other offering expenses, were $35 million.

Equillium Announces Closing of Public Offering of Common Stock

LA JOLLA, Calif., Aug.  13, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock at a public offering price of $7.00 per share. In addition, Equillium has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price less the underwriting discount. Equillium anticipates its gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $35 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about August 18, 2020, subject to customary closing conditions.

Equillium Announces Pricing of Public Offering of Common Stock

LA JOLLA, Calif., Aug.  13, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Equillium. Equillium also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Equillium Announces Proposed Public Offering of Common Stock

LA JOLLA, Calif., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the second quarter 2020.

News for Equillium Inc Stock (EQ)